Teva’s Ajovy Failure In Cluster Headaches Good For Lilly’s CGRP Inhibitor Emgality
Lilly's Emgality looks set to benefit from Teva ending clinical development of its CGRP antibody competitor in cluster headaches due to lack of efficacy in Phase III.
You may also be interested in...
Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.